ClinicalTrials.gg
RecruitingNCT06224218Updated May 16, 2024

Prostate Single Port & Laser Enucleation Comparison Trial

An interventional study of Single Port Robotic Surgery and Laser Surgery in Prostate Hyperplasia, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 88 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Planned enrollment
64th of 150
116 · median 83
Started
2024
with 10 others
No phase
63 of 188
13 open now
Primary completion
2027-01
later than 17 of 47 live
Registered
160th of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 64th largest by planned enrollment of the 150 interventional ones that give a count, is one of 11 that started in 2024, is one of 63 with no phase, reaches primary completion later than 17 of the 47 other live ones, and was the 160th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 88 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

Surgical treatments for benign prostatic hyperplasia (BPH) are necessary when non-procedural approaches fail to alleviate lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO). Open simple prostatectomy and laser enucleation are recommended for prostatic adenoma size greater than 80 ml. Minimally invasive approaches, such as robotic-assisted simple prostatectomy, have gained popularity due to their comparable outcomes with lower morbidity. The introduction of the da Vinci single-port (SP) robotic platform offers potential advantages, but its outcomes have not been thoroughly investigated.

This randomized controlled trial aims to compare the outcomes of SP simple prostatectomy performed using the da Vinci robotic platform versus thulium laser enucleation of the prostate for the treatment of BPH and BOO.

Read the detailed description

Patients diagnosed with symptomatic BPH and eligible for surgical intervention will be randomized to undergo either SP robotic simple prostatectomy or thulium laser enucleation of the prostate. Primary outcomes will include perioperative parameters (operative time, estimated blood loss, hospital stay), postoperative complications, and functional outcomes (urinary symptoms, urinary flow rate). Secondary outcomes will evaluate perioperative and postoperative complications, oncologic outcomes, and patient-reported quality of life measures.

In a recent retrospective study at UI Health from 2017 to 2021, investigators compared 103 procedures, SP robotic prostatectomy versus laser enucleation, 34 SP robotic prostatectomy and 69 laser enucleations. There was no difference in any complication at 30-day post-surgery (21.2% vs. 21.7%, p=0.9517). Investigators recognize SP robotic surgery leads to longer operating times, due to docking the instrument and closing the incision, as well as longer catheter times to allow the cystostomy to heal. While the laser enucleation may be considered less invasive, as no incision is required, the instrumentation of the urethra could lead to urethral strictures. This study aims to provide valuable insights into the clinical outcomes of single port simple prostatectomy using SP robotic platform, compared to laser enucleation of the prostate prospectively. The results of this trial will help guide clinicians and patients in selecting the most appropriate surgical intervention for symptomatic BPH, considering both functional outcomes and morbidity. Both procedures are currently performed at UI Health, they are FDA approved, therefore this is not a safety study. Subject insurance will not impact which subject will receive one procedure or the other, as both procedures are recommended on the American Urological Association guidelines for Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.

The study will be a randomized controlled trial comparing SP simple prostatectomy vs laser enucleation of the prostate. The study findings will improve clinical decision-making and aid in optimizing patient outcomes in the management of BPH.

03

Conditions studied

  • Prostate Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) who fail conservative treatment with drug therapy are eligible for surgical intervention.

Exclusion criteria

Exclusion Criteria:

  • Adults unable to consent Prisoners Cognitive impaired adults Coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Active comparator
    Single Port Robotic Prostatectomy

    Removal of the prostate using single port robot

    Procedure: Single Port Robotic Surgery

  • Active comparator
    Laser Enucleation of the Prostate

    Enucleation of the prostate with laser surgery

    Procedure: Laser Surgery

Interventions

  • ProcedureSingle Port Robotic Surgery

    Single port Robotic surgery will remove the whole prostate

  • ProcedureLaser Surgery

    Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.

06

What researchers measure

Primary outcomes

  1. Operative time

    Time in minutes from the start to finish of the procedure.

    Time frame: During procedure

  2. International Consultation of Incontinence Questionnaire Short Form

    How often do you leak urine? never 0 about once a week 1 two or three times a week 2 about once a day 3 several times a day 4 all the time 5 How much urine do you usually leak (whether you wear protection or not)? none 0 a small amount 2 a moderate amount 4 a large amount 6 Overall, how much does leaking urine interfere with your everyday life? 0 (not at all) and 10 (a great deal) 0 1 2 3 4 5 6 7 8 9 10 ICIQ score: sum previous questions. When does urine leak? never - urine does not leak before you can get to the toilet when you cough or sneeze when you are asleep when you are physically active/exercising when you have finished urinating and are dressed for no obvious reason all the time

    Time frame: Before procedure and 7 months after procedure

  3. Sexual Health Inventory for Men (SHIM)

    1. How do you rate your confidence to keep an erection? 1 Very low 2 3 4 5 Very high 2. How often were your erections hard enough for penetration? 1 Almost never 2 3 4 5Almost always 3. How often were you able to maintain your erection after you had penetrated your partner? 1Almost never 2 3 4 5Almost always 4. How difficult was it to maintain your erection to completion of intercourse? 1Extremely difficult 2 3 4 5Not difficult 5. When you attempted sexual intercourse, how often was it satisfactory for you? 1Almost never 2 3 4 5Almost always Add together the numbers. If the patient's score is 21 or less, erectile dysfunction (ED) should be addressed. 22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction

    Time frame: Before procedure and 7 months after procedure

  4. International Prostate Symptom Score I-PSS

    1. How often have you had a sensation of not emptying your bladder completely after you finish urinating? 0= not all 1. less than 1 time in 5 2. less than half the time 3. about half the time 4. more than half the time 5. almost always 2. How often have you had to urinate again less than two hours after you have finished urinating? 0 1 2 3 4 5 3. How often have you found you stopped and started again several times when you urinated? 0 1 2 3 4 5 4. How often have you found it difficult to postpone urination? 0 1 2 3 4 5 5. How often have you had a weak urinary stream? 0 1 2 3 4 5 6. How often have you had to push or strain to begin urination? 0 1 2 3 4 5 7. How many times did you most typically get up each night to urinate from the time you went to bed until the time you got up in the morning? 0 1 2 3 4 5 Sum previous questions to have the score: 0 - 7 = mildly symptomatic; 8 - 19 = moderately 20 - 35 = severely

    Time frame: Before procedure and 7 months after procedure

  5. Urinary flow rate

    Measure of the urine flow in mL/s

    Time frame: Before procedure and 7 months after procedure

  6. Post void residual volume

    Amount of urine retained in the bladder after a voluntary void measure with Ultrasound. Volume = length x width x height x 0.52

    Time frame: Before procedure and 7 months after procedure

  7. Blood loss during procedure

    Estimate blood loss in mL during procedure

    Time frame: During procedure

  8. Hospital stay after procedure

    Amount of time spent at the hospital after procedure measure in hours

    Time frame: From end of procedure to discharge home (up to 30 days )

Secondary outcomes

  1. Number of subjects with injuries related to surgical procedures.

    Descriptive report of complications during surgery.

    Time frame: During procedure

  2. Quality of life due to urinary symptoms

    If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that? 0 1 2 3 4 5 6 0= delighted 1. please 2. mostly satisfied 3. mixed 4. mostly unhappy 5. unhappy 6. terrible

    Time frame: Before procedure and 7 months after procedure

  3. Number of subjects with incidental cancer

    Pathology report of prostate tissue, presence or absence of prostate cancer.

    Time frame: 2 weeks after procedure

07

Study locations

1 of 1 sites recruiting
  • UI Health SCB Clinic Department of Urology
    Chicago, Illinois 60612, United States
    Recruiting
    • Ruben Sauer, MD · Contactrsauer1@uic.edu · 312-413-5288
    • Simone Crivellaro, MD · Principal investigator
08

References and documents

Publications

  • Talamini S, Lai A, Palmer C, van de Walle G, Zuberek M, Crivellaro S. Surgical treatment of benign prostatic hyperplasia: Thulium enucleation versus single-port transvesical robotic simple prostatectomy. BJUI Compass. 2023 Jun 22;4(5):549-555. doi: 10.1002/bco2.261. eCollection 2023 Sep. PubMed 37636211 ↗
  • Bove AM, Brassetti A, Ochoa M, Anceschi U, D'Annunzio S, Ferriero M, Tuderti G, Misuraca L, Mastroianni R, Cartolano S, Torregiani G, Lombardo R, De Nunzio C, Simone G. Robotic simple prostatectomy vs HOLEP, a 'multi single-center' experiences comparison. Cent European J Urol. 2023;76(2):128-134. doi: 10.5173/ceju.2023.204. Epub 2023 Apr 17. PubMed 37483855 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 25, 2024
StartActual
Jan 15, 2024
Primary completionEst.
Jan 15, 2027
CompletionEst.
Aug 15, 2027
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06224218
Responsible party
Simone Crivellaro (Urology Dpt, Vice Chair, Lawrence S. Ross Endowed Professor & Associate Professor of Urology Robotic, Section Chief, University of Illinois at Chicago) — Principal investigator
First posted
Jan 25, 2024
Start date
Jan 15, 2024
Primary completion
Jan 15, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
May 16, 2024

Study contacts

Ruben Sauer, MD
Contact
rsauer1@uic.edu
3124135288
Simone Crivellaro, MD
principal investigator · University of Illinois at Chicago, Department of Urology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion